DENVER, Oct. 21, 2026 (GLOBE NEWSWIRE) — (247marketnews.com<\/u><\/a>) \u2014 \u201cI wish someone had told me about that company.\u201d<\/p>\n That is a familiar reaction when a stock attracts attention after investors have spent months overlooking it. The harder task is recognizing a developing business story while the chart still gives the market reasons to look away.<\/p>\n NeOnc Technologies Holdings (Nasdaq: NTHI)<\/strong> is giving investors another development to examine. According today\u2019s announcement, NeOnc signed a Memorandum of Understanding with the Department of Health \u2013 Abu Dhabi to support research and clinical capability in oncology and central nervous system therapeutics.<\/p>\n 24\/7 Market News believes the announcement adds substance to a story that deserves a closer look: an investigational brain cancer platform with reported clinical data, expanding compassionate access and a broader framework for development in Abu Dhabi.<\/p>\n A Broader Research Framework in Abu Dhabi<\/strong><\/p>\n Signed on the sidelines of the Abu Dhabi Future Health Summit 2026, the MoU covers scientific exchange, specialist training, clinical development expertise and the generation and exchange of real-world evidence concerning CNS tumors.<\/p>\n The proposed collaboration includes work on trial design, endpoint selection, response assessment, neuro-oncology imaging and molecular diagnostics. These are practical elements of developing the people, methods and evidence needed to evaluate investigational treatments.<\/p>\n The parties will also assess opportunities for clinical research involving NeOnc\u2019s programs and explore a possible regional presence, including potential manufacturing, supply or distribution activities. The MoU is nonbinding and has a two-year term; specific clinical research and regional operating activities remain subject to separate agreements and applicable approvals.<\/p>\n In our view, the investor significance lies in the scope of that framework. If implemented, it could help NeOnc develop a more substantial base for clinical research and future regional activity.<\/p>\n Two Children Are Already Receiving Compassionate Care<\/strong><\/p>\n The announcement also describes activity already underway. Two children in Abu Dhabi are receiving investigational NEO100 through NeOnc\u2019s Compassionate Care program. A third child from India is expected to enter the program this week.<\/p>\n NeOnc is separately working to open a Phase 1 study of NEO100 in the Emirate. Its existing Abu Dhabi IND clearances support clinical research, with additional requirements, including separate Institutional Review Board approval, to be satisfied before trial enrollment.<\/p>\n \u201cFor families facing brain cancer, access to investigational treatments and clinical research opportunities matters deeply,\u201d said Amir F. Heshmatpour, NeOnc\u2019s Executive Chairman, President and Chief Executive Officer, in the announcement.<\/p>\n The update follows NeOnc\u2019s October 16 report of early improvement in a critically ill three-year-old boy receiving compassionate-use NEO100 in Abu Dhabi. According to his treating physicians, the child was breathing independently and beginning to move his legs after treatment began. The company described these as early observations in one patient, without establishing that NEO100 caused the improvement.<\/p>\n For families facing an aggressive brain tumor, the importance of access to research and investigational care is deeply personal. That human purpose remains central to NeOnc\u2019s development story.<\/p>\n Clinical Results Give Investors More to Evaluate<\/strong><\/p>\n In August, NeOnc reported that its 24-patient, open-label Phase 2a study of intranasal NEO100 in recurrent or progressive IDH1-mutant high-grade glioma met its primary endpoint. Six-month progression-free survival was 48.9%, compared with the study\u2019s pre-specified 20% benchmark.<\/p>\n The Abu Dhabi agreement adds a further development opportunity around a program that has already produced reported human clinical data.<\/p>\n Meanwhile, the reported NTHI short interest for September 30 totaled 757,739 shares.<\/p>\n If further studies support the early findings and the proposed collaboration leads to additional clinical development, we believe investors could have reason to reassess NeOnc\u2019s potential.<\/p>\n The recent chart shows where NTHI has been. The next clinical results and development milestones will help determine where the company goes from here.<\/p>\n About 24\/7 Market News<\/strong><\/p>\n In today’s fast-moving markets, visibility is everything and 24\/7 Market News (24\/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company\u2019s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24\/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com<\/u><\/a> to discuss how 24\/7 can help accelerate your company\u2019s visibility and valuation trajectory.<\/p>\n PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24\/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here<\/u><\/a>. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.<\/p>\n Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.<\/p>\n